Strides Pharma Science Limited (Strides) has recently informed exchanges that its step-down fully owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has obtained FDA approval for Fluoxetine Tabs 60 mg.
The company is now positioned to offer a complete portfolio of fluoxetine in 10 mg, 20 mg and 60 mg strengths for tablets and capsules, after the approval of the Fluoxetine Tabs 60 mg strength. According to IMS, the combined market size for Fluoxetine Capsules and Tablets is around US$ 130 Mn.
In the exchange filing, the company shared, “The addition of the Fluoxetine Tabs 60 mg will allow for enhanced flexibility in dosing, catering to a broader spectrum of patient needs. The Company plans to launch all three strengths in the near future. The Fluoxetine tablets will be manufactured at the company’s facility in Puducherry.”
